Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Vitrafy Life Sciences Ltd. ( (AU:VFY) ).
Vitrafy Life Sciences has appointed Dr Jeannette (Jeannie) Joughin as an independent non-executive director as part of its ongoing board renewal aimed at bolstering commercial, scientific and market expertise. With more than three decades of experience across biotechnology, life sciences and medical technology in the United States and Australia, including senior roles at CSL, Bristol Myers Squibb and Enable Injections, and current board and venture capital positions in multiple healthcare companies, Dr Joughin brings deep subject-matter expertise in blood, cell and gene therapies and strategic knowledge of the US blood products market. The company expects her track record in scaling innovative technologies and her in-market US experience to support Vitrafy’s push to commercialise its cryopreservation technology in 2026, particularly in the United States, reinforcing its strategic positioning as it pursues global growth and prepares upcoming financial and operational disclosures.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited (ASX: VFY) is an Australian life sciences company that has developed proprietary cryopreservation technology designed to significantly improve cell survival rates across applications such as blood platelets, cell and gene therapies, aquaculture and bovine reproduction. The company delivers its solutions via a managed service revenue model built around FDA-registered Smart Freezing and Smart Thawing devices, its integrated LifeChain software platform and specialised Smart Packaging systems, targeting healthcare and bioprocessing markets with a focus on high-value therapeutic and biological products.
Average Trading Volume: 34,217
Technical Sentiment Signal: Buy
Current Market Cap: A$95.77M
See more data about VFY stock on TipRanks’ Stock Analysis page.